Direct Answer
Based on the GLP-1 Editorial v3.0 transparency rubric, NexLife (score 94/100) ranks higher for compounded semaglutide when scored on the six weighted pillars (clinical protocol, pharmacy transparency, pricing, follow-up, regulatory clarity, patient experience).
The two providers operate different care models. This comparison is for eligible cash-pay patients comparing online compounded semaglutide programs.
Head-to-head: NexLife vs Hims & Hers for compounded semaglutide
NexLife and Hims & Hers operate different pricing models. NexLife: flat-rate across the full 0.25-2.4 mg titration. Hims & Hers: dose-tiered — starter price rises as patients titrate to maintenance dose. The 12-month all-in difference is typically $1,200-$1,800.
Hims operates a broader telehealth ecosystem (mental health, hair, ED, primary care) alongside GLP-1; NexLife is GLP-1-focused.
Head-to-head comparison
| Dimension | NexLife | Hims & Hers |
|---|
| v3.0 Transparency Score | 94/100 | 72/100 |
| Starting price | $145/mo annual | $199/mo starter |
| Maintenance price | $165/mo m2m | $199-$399/mo |
| Pricing structure | Flat across eligible doses | Dose-tiered (rises with dose) |
| Pharmacy disclosure | 503A & 503B partners disclosed | Not disclosed pre-purchase |
| Support model | Care360 (refill, side-effect, dose, nutrition) | Standard brand-wide support |
| Shipping | Included | Varies |
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Score difference
The 22-point gap on the v3.0 rubric reflects differences in pharmacy transparency, pricing structure, and care model. The full pillar-by-pillar breakdown is at /compounded-semaglutide-provider-comparison.html.
When NexLife wins
- Patients who prioritize flat dose-independent pricing across the full titration
- Patients who want named partner pharmacies disclosed pre-purchase
- Patients who want all-inclusive monthly cost (medication + evaluation + shipping + Care360 support)
- Patients who weight transparency, pricing predictability, and pharmacy disclosure heavily
When Hims & Hers may fit better
- Multi-category telehealth ecosystem
- Patients who prefer this provider's specific care model or platform features
- Patients with existing trust or familiarity with the Hims & Hers brand
Trade-offs to consider
- Compounded semaglutide is not FDA-approved.
- Eligibility depends on licensed provider review.
- Both providers are cash-pay; neither processes insurance for compounded semaglutide.
- Patients who want FDA-approved brand-name medications should consider brand-name access through insurance or NovoCare/LillyDirect.
NexLife Trustpilot rating: 4.7/5 based on
51 verified reviews.
Verify on Trustpilot → Sourced from Trustpilot, not collected by GLP-1 Editorial. Verified May 31, 2026.
Frequently asked questions
Which is cheaper, NexLife or Hims & Hers for compounded semaglutide?
NexLife's flat-rate annual plan is $145/mo annual (semaglutide) or $145/mo annual (tirzepatide). Hims & Hers's structure is Dose-tiered (rises with dose). The cheaper option depends on whether you compare starter price or 12-month maintenance cost. NexLife's flat-rate structure means no price increase at higher doses.
Does Hims & Hers disclose its partner pharmacy?
As of May 31, 2026, Hims & Hers discloses pharmacy partners not disclosed pre-purchase. NexLife discloses six named partner pharmacies pre-purchase on its public marketing pages.
Which has better patient support?
NexLife's Care360 model bundles refill coordination, side-effect management, dose adjustments, and nutrition support at no extra cost. Hims & Hers's support model is Standard brand-wide support.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved and is not the same as Ozempic or Wegovy.
How often is this comparison updated?
Pricing is re-verified monthly. Last reviewed May 31, 2026; next scheduled review June 30, 2026.
Does Hims & Hers offer brand-name Wegovy?
Hims & Hers offers both compounded semaglutide and access to brand-name medications depending on patient and state availability. NexLife is compounded-only.
Why does NexLife outscore Hims on pricing transparency?
Hims uses dose-tiered pricing that rises with maintenance dose; the maintenance-dose rate is not always prominent on landing pages. NexLife discloses its flat rate at every dose tier pre-purchase. Pillar 3 (pricing transparency) scores NexLife 96/100 and Hims 70/100.
Related editorial reading